GlaxoSmithKline earnings date
GlaxoSmithKline (GSKN) Q3 2026 Earnings Report
MX:GSKN Q3 2026 EPS Results
- Actual EPS
- MXN 27.01
- Consensus EPS
- MXN 24.77
- Beat/Miss
- Beat by +MXN 2.23
- One Year Ago EPS
- MXN 27.10
MX:GSKN Q3 2026 Revenue Results
- Actual Revenue
- MXN 222.16B
- Expected Revenue
- MXN 219.05B
- Beat/Miss
- Beat by +MXN 3.11B
- YoY Revenue Growth
- +3.62%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/28/2026
- Time
- Before Open
- Conference Call
- Wednesday, October 28, 2026
GlaxoSmithKline's next earnings date is estimated for February 3, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. GSK reported 5% sales growth, reaffirmed 2026 guidance, delivered strong cash generation, and highlighted substantial progress across launches, approvals, commercial growth, and the accelerated phase III pipeline. The main negatives were vaccine and inhaler market pressures, significant restructuring and financing costs, foreign exchange headwinds, ongoing uncertainty around the four-monthly APRETUDE formulation, and adoption or monitoring challenges for certain products.
GSK reconfirmed 2026 guidance, with sales expected in the upper half of the range, Core operating profit also expected in the upper half of the range, and margin on track to be more than 31% at constant rates; SG&A is projected to be broadly stable, royalties are now upgraded to around GBP 900 million for the year, R&D is expected to grow significantly ahead of sales as phase III starts increase from the 10 expected at the start of the year to now 22, EPS growth is expected to be in the low half of the range, full year interest is expected to be GBP 700 million-GBP 750 million, including around GBP 160 million relating to the acquisition of Nuvalent, and foreign exchange headwinds are expected to be -1% on sales and -3% on operating profit; GSK expects charges of up to GBP 1 billion in 2026 and remains on track to deliver a target of around GBP 10 billion CGFO at constant rates.
- Q3 Sales and Operating MomentumQ3 sales increased 5% to GBP 8.9 billion, core operating profit grew 5%, and core EPS increased 1%. Specialty medicines drove momentum, with specialty sales up 15%.
- Strong Cash Generation and DividendCash generation remained strong at GBP 7.4 billion year to date. The Q3 dividend was 17 pence, and GSK remains on track to deliver around GBP 10 billion of full-year CGFO at constant rates.
- 2026 Guidance ReconfirmedGSK reconfirmed 2026 guidance. Full-year sales and core operating profit are expected in the upper half of their respective ranges, margin remains on track to exceed 31% at constant rates, and SG&A is projected to be broadly stable.
- Late-Stage Pipeline AccelerationGSK has started 18 phase III studies in 2026, including 12 new starts in the quarter, with a further four on track to start before year-end. This is ahead of the original plan to start more than 20 phase III studies in 2026, and recruiting is underway in 18 of 22 planned starts.
- Recent Approvals and Oncology ExpansionJideytro and Hibsago received approvals ahead of their FDA PDUFA dates, while Jemperli received accelerated approval in locally advanced rectal cancer. GSK also received approval for a further Jemperli indication and has launched Jideytro in non-small cell lung cancer, generating GBP 3 million so far.
- Jideytro Clinical ProfileIn the ARROS-1 study of TKI-naive ROS1-positive patients, Jideytro produced a 94% overall response rate and a 15% complete response rate. Median duration of response had not been reached, while 86% of patients had a duration of response greater than 12 months. No CNS progression events were observed in patients without baseline metastases, and the response rate was 100% among patients with brain metastases at study entry.
- Neladalkib Development ProgressIn the phase I/II ALKOVE study, neladalkib achieved an 86% overall response rate in TKI-naive patients, with 91% of patients having a duration of response greater than 12 months. The phase III ALKAZAR study was more than 50% recruited, and FDA approval was anticipated in November.
- Ris-Rez Small Cell Lung Cancer DataIn Chinese phase III ARTEMIS-008 data for small cell lung cancer, Ris-Rez reduced the risk of death by 54% and produced median overall survival of 18.5 months. The global EMBOLD 101 study showed a 61% response rate in its small cell lung cancer cohort, consistent with the 58% overall response rate in ARTEMIS-008. The global phase III EMBOLD SCLC-301 trial is recruiting well.
- Ris-Rez Osteosarcoma DataIn the ARTEMIS-011 study of relapsed refractory osteosarcoma, Ris-Rez reduced the risk of disease progression or death by 67%. The global EMBOLD Sarcoma-202 phase II study started earlier in the year and is recruiting well. More than 1,000 patients have received Ris-Rez across the global EMBOLD program.
- Mo-Rez Ovarian Cancer ActivityGlobal phase I BEHOLD-1 data showed median progression-free survival of around 11 months for Mo-Rez in a non-biomarker-selected ovarian cancer population, compared with around six to eight months for current standard of care. Recruitment has started for five phase III trials in ovarian and endometrial cancer.
- Jemperli Rectal Cancer ResultsIn the AZUR-1 study of dMMR locally advanced rectal cancer, over two-thirds of patients achieved a complete clinical response. After two years of follow-up, no disease recurrences were reported among patients who responded. Earlier data showed 68% of participants had no detectable signs of cancer one year or more after treatment.
- mRNA Flu Vaccine ProgressGSK's mRNA flu vaccine candidate received FDA Fast Track designation and targets both hemagglutinin and neuraminidase. In phase II, it produced stronger immune responses against both targets than a high-dose comparator. A phase III study in more than 50,000 adults aged 65 and over began in September, with more than two-thirds of the season's enrollment target already recruited.
- Cabenuva and APRETUDE GrowthCabenuva sales grew 35% in the quarter, with more than 75% of switches in the U.S. continuing to come from competitors. APRETUDE sales increased 21% and held market share. ViiV grew 10% in the quarter and for the year.
- Cabenuva Pipeline ProgressThe phase III-B CROWN study showed superiority for Cabenuva versus daily oral standard of care in an unsuppressed viremic population. The CUATRO study of a four-monthly formulation was fully recruited ahead of expectations and remained on track to read out next year. Six-monthly formulations VH-184 and VH-499 were progressing as planned through phase II, with a pivotal study still intended for 2028.
- Respiratory Portfolio GrowthNucala sales increased 18%, driven by its COPD launch, with international growth of 21% and market leadership achieved in China. Trelegy grew 8% in the U.S. and 11% internationally. GSK maintained market leadership in the triple inhaler class in COPD and asthma, while the IL-5 class grew 12% versus last year.
- Exdensur Launch MomentumExdensur sales were GBP 27 million in Q3. Following the U.S. J-code and average selling price milestones, new prescribers increased 68% and new patient starts increased 74%, including patients receiving a free first dose through the Fast Start program. More than two-thirds of insured patients were covered.
- Blenrep Commercial ProgressBlenrep is approved in 52 markets and is continuing to launch globally. It became the market leader in second-line NICE-approved regimens in the U.K. In the U.S., repeat prescribers accounted for about one-third of sales and were increasing. Updated NCCN guidelines included DREAMM-7 and DREAMM-8 data in the second-line-plus population beyond the U.S. label.
- Meningitis Portfolio StrengthThe meningitis portfolio grew 12%, driven by the meningitis B-containing portfolio in the U.S. and the first full back-to-school season for Penmenvy. GSK now has more than 90% share of the global MenB market.
- Hibsago Launch and Reimbursement ProgressHibsago was approved in Japan and the U.S. and is positioned as the first finite treatment for chronic hepatitis B with the potential for a functional cure. Japan granted a 50% usefulness premium and an additional 10% premium for SENKU designation. Patients were already receiving therapy in Japan and the U.S., and China regulatory discussions were ongoing with plans to launch in the private market when available.
- Hibsago Clinical Response IndicatorsGSK stated that more than 60% of patients with baseline surface antigen below 1,000 could reach below 100 surface antigen for at least one year post-treatment. Additional long-term data through 48 weeks and analyses of surface antigen loss and health outcomes were scheduled for presentation at AASLD.
- Shingrix China Demand ImprovementShingrix injections in arms in China were approximately 300,000 per month, up 60% versus last year. China inventory declined from around 4.3 million doses in summer last year to 1.4 million doses as of August, equivalent to about 1.5 months of demand.
- Shingrix U.S. Penetration and Future StudiesThe U.S. Shingrix immunization rate was 46%, up 3 percentage points and within the previously stated 2%-4% range. GSK is conducting studies in MACE and dementia, including two pragmatic RCTs in Finland and Denmark expected to enroll about 200,000 adults, with initial results expected in 2029 and a first CVD readout at the end of 2027.
- Gross Profit and Resource EfficiencyGross profit increased 7%, supported by product mix and efficiencies. SG&A increased 1%, including Nuvalent costs, while management said the result demonstrated resource allocation and improved ROI. Operating profit grew 5% with a broadly stable margin.
- Improved Cash Flow and Balance SheetYear-to-date CGFO was GBP 1.1 billion ahead of last year, and free cash flow was up GBP 1.8 billion, including $650 million from the out-license of linerixibat and the special dividend from the ViiV shareholding change. Net debt to core EBITDA was 1.8x after the Nuvalent acquisition.
- Food Allergy OpportunityGSK expects a phase IIb readout for ozureprubart in food allergy in 2027 and aims to start phase III in the second half of next year. Management cited approximately 17 million people with some form of food allergy in the U.S., including about 1.6 million with clinically relevant disease, and stated that ozureprubart has approximately twice the potency of Xolair with the potential for three-monthly dosing.
- Hengrui Collaboration ExpansionThe Hengrui collaboration includes a PDE3/4 program in early clinical development targeting a metered-dose inhaler opportunity, plus 11 other undisclosed targets. GSK said it is actively working with Hengrui to select the next programs for disclosure.
MX:GSKN Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 03, 2027 | 2026 (Q4) | 13.76- | 12.96 | ― | ― |
| Oct 28, 2026 | 2026 (Q3) | 24.7727.01 | 27.1 | -0.34% (-0.09) | |
| Jul 28, 2026 | 2026 (Q2) | 23.0624.96 | 22.99 | 8.58% (+1.97) | |
| Apr 29, 2026 | 2026 (Q1) | 21.4823.36 | 22.3 | 4.75% (+1.06) | |
| Feb 04, 2026 | 2025 (Q4) | 11.9412.96 | 10.81 | 19.97% (+2.16) | |
| Oct 29, 2025 | 2025 (Q3) | 23.3827.10 | 24.05 | 12.68% (+3.05) | |
| Jul 30, 2025 | 2025 (Q2) | 21.7822.99 | 20.74 | 10.85% (+2.25) | |
| Apr 30, 2025 | 2025 (Q1) | 19.4422.30 | 20.03 | 11.33% (+2.27) | |
| Feb 05, 2025 | 2024 (Q4) | 9.1010.81 | 13.69 | -21.06% (-2.88) | |
| Oct 30, 2024 | 2024 (Q3) | 21.4324.05 | 22.73 | 5.81% (+1.32) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


